Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Heat shock protein 90 (Hsp90) is a crucial molecular chaperone implicated in cancer progression.
• Numerous Hsp90 inhibitors have been investigated, but none have gained FDA approval due to toxicity and efficacy issues.
• Lack of isoform selectivity is a key challenge limiting the therapeutic potential of existing Hsp90 inhibitors.

Purpose of the Study:

• To review classic pan-Hsp90 inhibitors based on binding site classification.
• To illustrate drug design strategies for Hsp90 inhibitors.
• To summarize current isoform-specific Hsp90 inhibitors, their discovery, and potential applications.

Main Methods:

• Literature review of Hsp90 inhibitor research.
• Classification of pan-Hsp90 inhibitors by binding sites.
• Analysis of design strategies in Hsp90 inhibitor drug discovery.
• Summary of isoform-specific Hsp90 inhibitors and their development.

Main Results:

• Classic pan-Hsp90 inhibitors targeting different binding sites were categorized.
• Drug design strategies for developing Hsp90 inhibitors were outlined.
• Current isoform-specific Hsp90 inhibitors, their discovery pathways, and therapeutic indications were compiled.

Conclusions:

• Developing isoform-selective Hsp90 inhibitors is a promising strategy to improve cancer treatment efficacy and reduce toxicity.
• Targeting specific Hsp90 isoforms may unlock new therapeutic avenues for cancer and other diseases.
• Further research into isoform-specific inhibitors is warranted for clinical advancement.